This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Stocks in this article: ARNA PPHM VVUS NPSP DNDN

Back to Arena: Scott writes, "I recommend you quit bashing Arena. The article you put out today is incorrect. The article suggests that people short Arena. This article is not correct. I have called Arena and let them know about your article. Plus you are only negative on this company. Are you shorting? Please don't put out negative stuff on Arena if it isn't true. If I feel you are bashing Arena and you have incorrect information in an article written again I may need to get a lawyer. I recommend you do some dd sic on Arena before you put out false information."

Responding to Scott's email would be unfair piling on, so I'll just keep my mouth shut.

George writes, "Just who is paying you to write the blatantly negative articles on Arena Pharmaceuticals? You have repeated some of the pieces ad nauseum sic time after time and often just before important news is about to arrive. My guess is your latest two, yes two at one time, a new low, is because Eisai is just about to announce a launch date for Belviq when the DEA finalise sic Schedule IV and Arena receive a landmark $65 million payment. Sorry that you will have to report back to your masters eventually that despite all your heroic rear guard actions, their shorting of Arena was totally misguided and they have lost millions."

Bob W. writes, "Just who is paying you to write the blatantly negative articles on Arena Pharmaceuticals? You have repeated some of the pieces ad nauseum sic time after time and often just before important news is about to arrive. My guess is your latest two, yes two at one time, a new low, is because Eisai is just about to announce a launch date for Belviq when the DEA finalise sic Schedule IV and Arena receive a landmark $65 million payment. Sorry that you will have to report back to your masters eventually that despite all your heroic rear guard actions, their shorting of Arena was totally misguided and they have lost millions."

Huh. George and Bob's emails are identical, even down to the misspelling of "ad nauseam" and "finalize." If I were paranoid, I'd think there was a conspiracy afoot to pump shares of Arena!

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,444.11 +56.90 0.33%
S&P 500 2,031.10 +1.55 0.08%
NASDAQ 4,705.1710 +23.6740 0.51%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs